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Abstract 
Fragment-based drug discovery (FBDD) is well suited for discovering both drug leads and 
chemical probes of protein function: it can cover broad swaths of chemical space and allows 
the use of creative chemistry. FBDD is widely implemented for lead discovery in industry, 
but is sometimes used less systematically in academia. Design principles and implementation 
approaches for fragment libraries are continually evolving, and the lack of up-to-date 
guidance may prevent more effective application of FBDD in academia. This Perspective 
explores many of the theoretical, practical, and strategic considerations that occur within 
FBDD programs, including the optimal size, complexity, physicochemical profile, and shape 
  
profile of fragments in FBDD libraries, as well as compound storage, evaluation, and 
screening technologies. This compilation of industry experience in FBDD will hopefully be 
useful for those pursuing FBDD in academia. 
 
Rules are for the obedience of fools and the guidance of wise men. 
Harry Day, Royal Air Force (1898-1977) 
 
Introduction  
 
As academia expects to play an increasing role in target validation and drug discovery, 
lessons that have been hard won in industry must become available so that they can be 
adopted and built on, and not poorly implemented or wastefully reinvented. Fragment-based 
drug discovery (FBDD) has emerged over the last 20 years as a highly successful way to find 
quality leads for subsequent optimization into drug candidates and approved new medicines. 
FBDD involves screening compounds that generally have fewer heavy atoms than is typical in 
a high throughput screening collection. Hit-identification methods must be adapted for the 
smaller size of fragments, and so require sensitive biophysical methods or higher 
concentration biochemical assays.  
 
In this Perspective we have tried to collate the collective experiences of authors from several 
companies intimately involved in the development of FBDD so as to help the wider adoption 
and effective implementation of FBDD in academia and smaller start-ups. 
 
In theory, a well-chosen fragment library samples an astronomically greater proportion of 
chemical space than a well-chosen high throughput screening (HTS) library can ever do.1,2 
  
This gives researchers the confidence that there will be fragments in the library that sample 
chemical space as thoroughly as possible. As a result, fragment hits form high-quality 
interactions with the target, usually a protein, despite being weak in potency.3 In fact, hit rates 
from fragment screens are sometimes used to assess the chemical tractability of a target. 
Fragment hits often show unique, often enthalpy-driven thermodynamic binding profiles.4 
Even small fragments offer enormous scope for growing into larger molecules.  
 
Structure-based drug design (SBDD) is nearly always used to help focus synthetic exploration 
of the fragment for ways to boost binding affinity and guide other properties needed for a 
successful drug.5 The careful use of SBDD allows medicinal chemists to control the physical 
properties of the growing fragment, ensuring that any additional molecular weight and 
lipophilicity also produces an acceptable increase in affinity.6 Ligand efficiency metrics are 
often used to judge whether increases in affinity are acceptable.7 As mentioned above, an 
alternative use of fragments is to assess the chemical tractability of a target,8 but the design 
and screening principles discussed here are broadly the same for such usage.  
 
 
Design principles for fragment libraries 
 
In 2003, Congreve et al. analyzed the results from a relatively small number of fragment 
screens and proposed that “hits seem to obey, on average, a “Rule of Three (RO3)” in which 
molecular weight <= 300 Daltons, the number of hydrogen bond donors <=3, the number of 
hydrogen bond acceptors is <=3 and cLogP is <=3”.9 The molecular weight and cLogP 
criteria were enthusiastically adopted by the fragment community, whereas the hydrogen 
bond criteria have been less frequently used, in part because of ambiguities in the way 
  
acceptors and donors are defined.10 Ten years later, the RO3 concept is still widely employed, 
but the successful design of fragment libraries incorporates many other factors, informed by 
years of fragment screening. 
 
The first consideration is the number of compounds to be included in the library; this is in part 
driven by the detection technology to be used in fragment screening. Higher throughput 
techniques, such as high concentration screening (HCS) using for example a biochemical 
assay, are not usually as sensitive as lower throughput biophysical techniques. In general, less 
sensitive techniques require more potent fragments which are likely to be more complex (that 
is, larger) compounds. (See fragment complexity section below.)11 This in turn requires larger 
libraries, as the probability of any one fragment being a hit exponentially declines with the 
increased complexity of the ligand. More typically, fragment libraries are screened using 
sensitive biophysical techniques and the fragment library need only consist of a few thousand 
compounds with molecular weights between about 140 and 230 Daltons.  
 
Other factors that will be discussed in detail in this article include ensuring that libraries: 
(i) Sample relevant chemical space by including key pharmacophores that can 
drive fragment binding. 
(ii) Contain an appropriate size distribution and a balance of differently shaped 
fragments (see section on 3D metrics) of appropriate complexity. Overly 
complex fragments have decreased hit rates due to functionalities that interfere 
with binding; overly flexible ones could have lower affinities due to the 
entropic costs of binding. 
(iii) Contain a diversity of synthetically accessible growth vectors so that fragment 
hits can be effectively optimized into lead compounds.12 
  
(iv) Avoid groups known to be associated with high reactivity, aggregation in 
solution, or persistent false positive data.13 
 
Additionally, fragment libraries will typically be subjected to extensive initial and ongoing 
quality control (QC) analyses under conditions relevant to both the storage and screening of 
the samples. These should include quantitative assessments of the purity, identity, stability 
and solubility of the fragments, together with more specific analyses such as the aggregation 
properties of the fragments.  
 
For difficult targets, such as protein-protein interactions, a good library offers the highest 
chance of identifying fragment hits that might be optimizable into lead compounds. For more 
tractable targets, even relatively poorly constructed libraries will yield some fragment hits, but 
the optimization of those hits into high quality lead compounds will still be heavily dependent 
on the quality and diversity of the output from the fragment screen.  
 
 
Screening technologies 
 
Technologies used for fragment screening must be compatible with the smaller size, reduced 
complexity and consequently lower affinity of fragments. While HTS assays often identify 
compounds with strong affinity (10 µM is a typical lower limit), fragment hits typically have 
weaker affinities in the 100 µM – 10 mM range, and thus the screening methodology must 
provide 100-1000 fold higher sensitivity. Thus, while HTS routinely use biochemical assays, 
fragment screening generally utilizes more sensitive biophysical technologies, as 
demonstrated by polls conducted on the blog Practical Fragments (Figure 1.)14 
  
 
 
 
 
Figure 1. Poll results on the Practical Fragments blog on the use of fragment screening 
techniques. SPR – surface plasmon resonance based biosensor technology, MS – mass 
spectrometry, ITC – isothermal titration calorimetry, Affinity – (AC) affinity 
chromatography, CE – capillary electrophoresis, BLI – biolayer interferometry, MST - 
microscale thermophoresis. Results were collected from 97 responders split roughly evenly 
between academia and industry. 
 
In 2011 SPR and ligand-detected NMR were clearly the most popular techniques followed by 
the thermal shift assay. The overall picture had not changed very much in 2013; however, the 
use of functional biochemical screening and X-ray crystallography was clearly increasing. 
The increase in functional biochemical screening may be due to improved diligence in 
avoiding false positives, the ease of running biochemical screens and/or the desire to use an 
orthogonal screen to a biophysical method. X-ray crystallography is less often used for 
  
primary screening because of its lower throughput. The increasing use of X-ray 
crystallography is therefore more likely attributable to the importance of structural 
information for effective FBDD. It should be noted, however, that X-ray crystallography 
techniques are moving towards higher-throughput as exemplified by the CSIRO Collaborative 
Crystallization Centre in Melbourne, Australia. Similar reasoning applies to protein-detected 
NMR and ITC reaching 30% and 20%, respectively in 2013. These methods are also often 
used as follow-up assays (structural and thermodynamic characterization) rather than primary 
screening technologies due to the demands for protein labeling and/or quantity.   
 
Those pursuing FBDD increasingly use orthogonal methods to assess hits: the average 
number of methods used increased from 2.4 in 2011 to 3.6 in 2013.14 Of course, only so much 
can be read into a self-selected poll on a blog. However, similar results were observed when 
Swain analyzed 165 published fragment screening programs reporting 620 hits against 116 
different targets. In particular, individual programs employ multiple techniques (Figure 2).15 
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Figure 2. Fragment screening technologies used in published FBDD studies (adapted from ref. 
15, November 2013)  
 
Based on these analyses it seems that the major screening technologies in use for FBDD are 
SPR, ligand- and protein-detected NMR, X-ray crystallography, thermal shift and biochemical 
assays. Since all of these methods have been extensively reviewed previously13,16 here we 
focus only on compound library related issues such as assay sensitivity (i.e., the ability to 
detect weak hits), specificity (i.e., the ability to discriminate between separate binding events), 
throughput and hit rate (Table 1). The propensity for false positives / false negatives in 
particular can be operator-dependent and even subjective and depends upon a definition of 
“hit.” For example, biochemical screens will tend to have a higher false negative rate 
compared to NMR because of the lower sensitivity rather than a particular issue that can be 
solved by assay design. On the other hand, the false positive rate can be strongly influenced 
by assay format and compound selection. 
 
Method Sensitivity 
limit 
Specificity 
assessment 
Throughput Structural 
information 
Propensity for 
false positive/ 
false negative 
Biochemical high M + high none high FP/FN 
Ligand-NMR low mM - medium some medium FP 
Protein-
NMR 
low mM + low high low FP/FN 
SPR high M + medium  none medium FP 
Thermal shift 
high M, 
low mM 
- high none high FP/FN 
  
X-ray mid mM  + low high low FP/ high FN 
 
Table 1. Sensitivity limit, feasibility of assessing specificity, throughput, structural 
information and false positive (FP) and false negative (FN) information on technologies most 
frequently used for fragment screening. The table gives an indication of typical output from 
properly configured experiments.  
 
The use of particular libraries for different screening technologies is not strictly necessary as 
reflected in general fragment libraries commercialized by many vendors and screened in 
multiple FBDD programs. However, the different sensitivities and specificities of the multiple 
technologies do impact the overall design principles of libraries (Figure 3). The sensitivity 
and specificity of the given screening technology determines the assay concentration that 
should be used for the identification of active fragments. To reach this concentration the 
library should contain fragments with adequate solubility. Since high solubility is reliant on 
appropriate physicochemical properties, this requirement inevitably limits the distribution of 
MW and logP of the library screened. Consequently, the affinity of fragment hits that can be 
found is impacted by the screening method used because of the requirements of the initial 
library selection.  
 
 
  
Figure 3. Relationship of assay sensitivity and specificity and physicochemical properties of 
the screening library. Sensitivity and specificity of the assay technology affect the solubility 
requirements for the library through the assay concentration needed for the detection of a 
binding event. These in turn influence the molecular weight, logP and likely affinity range of 
fragments from the library that sets limits for the assay concentration used to identify suitable 
hits.  
 
However, varying attributes of the most common screening technologies (summarized in 
Table 1) do affect the kinds of hits, false positives, and false negatives that will emerge from 
screening a library.  
 
Different levels of sensitivity will influence the optimal concentration of the compounds to be 
screened. NMR, X-ray and thermal shift assays are routinely performed with millimolar 
compound concentrations, while SPR and especially biochemical assays  use high micromolar 
concentrations. In addition, some screening methods are more tolerant of lower solubility 
compounds than others. For example, X-ray crystallography requires compounds to have high 
occupancy in the protein in order for a hit to be detected and thus requires high solubility, 
whereas ligand-observed NMR can identify fragments that bind with much lower occupancy.  
 
Thus, the sensitivity and specificity of the assay technologies can require different 
physicochemical properties of the fragment library. In addition, the false positive/false 
negative rates are influenced by the characteristics of the fragment library screened. Many 
false hits are due to a compound’s interference with detection technology in a way that 
wrongly suggests interaction with the target protein. 
 
  
Promiscuity is generally considered to be a deleterious property of drug leads except in cases 
where polypharmacology may be desired. However, in the context of fragment screening, the 
situation is more complicated. One source of promiscuity can arise from the fragment itself, 
whereby some types of molecules (e.g. promiscuous 2-aminothiazoles, or PrATs)17 are 
frequent hitters in a broad range of assays. However, as some approved drugs contain 2-
aminothiazoles, it is possible to evolve selectivity from such promiscuous starting points. The 
fact that an aminothiazole has many H-bond interaction opportunities suggests that 
substitution on one of the donor or acceptor atoms may well give the first step towards 
selectivity. Certain small halogenated fragments such as 4-bromopyrazole have also been 
reported as being promiscuous.18 The opportunity for building in selectivity to promiscuous 
kinase fragment hits has been widely demonstrated19 while Merck has provided a further 
example of this approach with the phosphodiesterase PDE10.20  
 
It is important to distinguish between such promiscuous fragments that may bind selectively 
to multiple sites on different proteins from fragments that act pathologically. These “frequent 
hitters” include PAINS (Pan Assay INterference compounds), which often react covalently 
with proteins or interfere with the assay, 21,22 and aggregators, which are especially 
problematic at high concentrations.23 Although the structural moieties in PAINS were 
identified in a biochemical assay using only one detection technology, these compounds have 
been reported to be active in many different assays and are often missed by reactivity filters.21  
 
Finally, the throughput of the screening technology obviously impacts the size of the library 
screened. These factors together are reflected in the hit rates observed for fragment libraries 
screened against multiple targets using different screening technologies (Table 2). 
 
  
Library Number of 
fragments 
Technology # 
screens 
Hit rate Ref. 
Min Max Average 
AstraZeneca 600-40000 Biochem 7 0.2% 33% 7% 24 
Genentech Not stated SPR 13 2.6% 14.9% 7.5% 25 
GSK kinase* 1064 Biochem 30 2.2% 62.2% 26.2% 26 
Novartis 2826 NMR Not 
stated 
3% 30% 2-8% 27 
Pfizer 2592 NMR 13 2.8% 12.6% 6.9% 28 
Vernalis 1063 NMR 12 0.4% 7.3% 3.2% 29 
 
Table 2. Hit rates observed for fragment libraries screened against multiple targets using 
different screening technologies. *Note the GSK kinase library was specifically selected to 
have likely kinase binding motifs, hence the high hit rate. 
 
It should also be noted that the definition of a screening hit is subjective and often influenced 
by the goals and constraints of the project as well as technical skills and expertise of relevant 
team members.  
While using screening technologies in parallel can compensate for weaknesses in each assay 
used, selection of particular screening technologies is not always straightforward since 
performance depends on the assay conditions, the library and the nature of the target itself. In 
the next section we summarize case studies using different technologies, screening the same 
library against the same target. These case studies illustrate the value of orthogonal assays to 
help pinpoint true hits. However, some promising starting points may not appear active in all 
of the assays, so judicious follow-up is required. 
 
  
Case studies with two or more screening technologies 
 
 HIV integrase: Wielens and coworkers screened a 500 member fragment library 
against HIV integrase using STD-NMR and SPR.30 NMR screening was performed 
with 50 cocktails of 10 compounds (each at a concentration of 1 mM) and identified 
84 active fragments from which 62 were validated by protein-observed NMR 
experiments. In a parallel screening effort, the same library was tested as individual 
compounds by SPR at 500 M concentration and yielded 16 hits validated by 
concentration-dependent SPR studies. Interestingly, no hits were confirmed by both 
the STD-NMR and SPR assays. Furthermore, the 6 hits co-crystallized from the 16 
SPR hits did not overlap with the 15 hits co-crystallized from the 62 NMR hits. In this 
case the SPR hit rate was significantly lower (3%) than that from NMR (13%). In 
addition to different screening concentrations and buffers (pH 7.4 vs pH 8.5 for SPR 
and NMR screening, respectively) assay sensitivity might be one of the major reasons 
for the significantly different hit rates; the NMR screen was more sensitive to weak 
binders.  
 Checkpoint Kinase 2: Montfort et al. investigated the performance of biochemical 
and thermal shift assays by screening 1869 fragments against Checkpoint Kinase 2.31 
Biochemical screening utilized an AlphaScreen assay performed at 300 M compound 
concentration and resulted in 45 non-aggregating hits out of which 20 did not cause 
assay interference as validated in dose-response studies. The thermal shift assay was 
carried out at a considerably higher compound concentration of 2 mM and gave 63 
hits, a significantly higher hit rate (3.4%) as compared to that of the AlphaScreen 
assay (1.1%). Comparing the hit lists, 12 fragments were identified by both assays and 
interestingly the authors found good correlation between Tm and IC50 values. The 
  
majority of hits, however, were found by only one technology. The biochemical and 
thermal shift assays respectively found 31 and 49 non-overlapping active fragments. 
Crystallization efforts were significantly more successful for overlapping hits since 8 
of the 12 dual hits were confirmed by X-ray crystallography compared to only one 
fragment out of the 49 identified by the thermal shift assay alone. The need for 
different screening concentrations was due to the limited DMSO tolerance of the 
biochemical assay although it showed generally higher sensitivity towards less active 
hits. 
 p38α kinase: The BioFocus fragment library was screened against p38α kinase using 
SPR and two biochemical assays including a mobility shift and fluorescence life time 
assays.32 266 fragments from the BioFocus library were screened by SPR in 200 M 
and 1 mM compound concentrations and gave 102 primary actives. The mobility shift 
assay was performed in both 200 M and 1 mM concentrations and identified 39 
validated hits. In analyzing the hit lists the authors concluded that only 9 out of the 
102 SPR hits were found by the mobility shift assay. In contrast, there was only one 
fragment out of the 10 identified by the biochemical assay that was missed by SPR. 
Hits identified by the mobility shift assay were also investigated by a fluorescence life 
time assay that confirmed 80% of them. These results indicate that the hits from the 
two biochemical assays correlate well but these are very different from those of the 
SPR assay. 
 MMP12 and Trypsin: Boettcher and coworkers tested 352 fragments at 1 mM 
concentration using three biochemical (fluorescence life time, fluorescence intensity, 
mobility shift) and two biophysical tests (SPR and protein- detected NMR) against 
Matrix metalloprotease MMP12 and Trypsin.33 The authors did not compare the hit 
  
lists quantitatively but focused the comparison on false positive (FP) and false 
negative (FN) rates compared to NMR actives as reference (Table 3). 
 
Technology 
MMP12 Trypsin 
FP FN FP FN 
FLT 13% 0% 13% 8% 
FI 5% 7% 8% 13% 
MSA 7% 15% 3% 9% 
SPR 11% 7% 3% 27% 
 
Table 3. False positive (FP) and false negative (FN) rates relative to NMR observed 
for different screening technologies (FLT – fluorescence life time, FI – fluorescence 
intensity, MSA – mobility shift assay) used for fragment screening against MMP12 
and Trypsin 
 
Comparison of FP and FN data revealed that biochemical assays performed similarly 
and SPR was comparable to them. The high false negative rate in the trypsin SPR 
assay was attributed to the weak response level due to low protein loading of the chip. 
The authors emphasized the importance of high solubility – influenced by the 
composition of the library - that should be determined by NMR rather than using a 
dynamic light scattering (DLS) assay. 
 HSP90: Hubbard et al. screened 111 Vernalis fragments against HSP90 using NMR, 
SPR, thermal shift and biochemical assays.34 The thermal shift assay (TSA) was 
conducted at 2 mM concentration; all the other tests were run at 500 M. The authors 
analyzed the correlation between different hit lists (Table 4). 
  
 
 SPR Biochem TSA 
NMR 90% 74% 74% 
SPR - 73% 76% 
Biochem  - 73% 
 
Table 4. Overlap between the hit lists of different screening technologies used for the 
identification of HSP90 inhibitors 
 
These results suggest that hits identified by NMR and SPR largely overlapped, but the 
hits of the third biophysical method (TSA) differed somewhat. This difference can be 
rationalized by the lower sensitivity of the thermal shift assay. Similarly, the 
correlation between biochemical and biophysical hits was also lower. 
 Endothiapepsin: Schiebel et al. screened a 361 member fragment library against 
endothiapepsin using biochemical and two biophysical techniques (STD NMR and 
thermal shift assay) in 1mM, 300 M and 2.5 mM concentrations, respectively.35 The 
highest hit rate was found for biochemical screening (17%) followed by NMR (11%) 
and thermal shift assay (8%). It is important to note, however, that the authors neither 
tested assay interference nor aggregate formation. Hit lists obtained by the three 
screening methods were compared (Figure 4). 
  
 
Figure 4. Venn diagram of biochemical, NMR and thermal shift hit lists obtained by 
screening against endothiapepsin 
 
The different assays were performed under similar conditions including the buffers. 
Screening concentrations and also hit selection criteria, which are usually based on 
previous screening experience, were different. More importantly, however, the 
methodologies applied show very different sensitivity in detecting weak binders. 
These factors likely explain the limited overlap between the hits lists. The authors used 
the hit lists from all three assays to pick which compounds to explore further with 
crystallography. In contrast to the biochemical hits, all of the unique NMR and more 
than half of the unique thermal shift hits were crystallized successfully.  
 Multitarget studies: In a large scale study a Novartis team reported screening a 1400 
member fragment library in 35 campaigns using biophysical (NMR, SPR, TSA) and 
biochemical (high concentration screening, CE, TR-FRET) assays.36 One of the major 
conclusions of this study is that different screening technologies provide hits with 
different physicochemical profiles on a given target, although there is a pronounced 
target dependency as well: NMR identified larger and more hydrophobic hits than TR-
  
FRET on one target but this was reversed on another. Although hit rates generally 
increased for larger and more lipophilic molecules, SPR hit rates were typically higher 
than TSA hit rates. This was partially rationalized by the non-specific binding of 
fragments to the chip surface. The lower hit rates obtained by thermal melting are 
likely a result of uncertainty as to how to handle results indicating thermal 
stabilization with lower Tm when a ligand binds. The complementary benefits of using 
both a biochemical and a biophysical assay are highlighted as being particularly 
effective in the detection of genuine fragment hits. (This has also been pointed out by 
the GSK group 37 in a similar meta-analysis which incorporates a broad discussion of 
the use of FBDD techniques.) The Novartis group does conclude that some fragments 
are “frequent hitters” although they consider them as “privileged fragments”, because 
there is often an opportunity to build selectivity while evolving fragments.  
 
Analyzing the active fragments from 35 campaigns on 20 targets it was interesting to 
see that 63% of the screened fragments never came up as hits. In contrast, the team 
identified privileged fragments that were found to be high value library members 
because they were active on more than one target.  For more detailed analysis the 
authors selected two campaigns that used five different screening technologies and 
investigated all of their combinations. This analysis revealed that there is better 
complementarity between biochemical and biophysical tests than two biophysical 
methods. Therefore the authors suggested that a combination of biochemical and 
biophysical technologies would provide greater chemical coverage. It seems likely that 
the limited overlap of biochemical and biophysical methods is strongly related to the 
different sensitivity and specificity of these techniques, and that should be considered 
when designing screening libraries. On the other hand, higher assay concentrations 
  
available for biophysical tests might generate higher numbers of false positives that 
could be reduced by the use of orthogonal techniques. 
 
It is important to emphasize that a legitimate hit may be missed in orthogonal assays, in 
particular when one method is more sensitive than another. Demanding agreement in all 
assays will limit detection to the least sensitive method, which may not be desirable, since 
even extremely weak fragments with no functional activity can be progressed to potent 
leads.38  
 
 
Fragment complexity and ligand efficiency 
  
Hann et al. introduced the concept of Molecular Complexity and its application to FBDD as a 
formalism for helping to understand the challenges and opportunities of fragments.11 This 
concept was inspired by examining protein-ligand interactions in crystal structures, which 
revealed that most interactions observed were productive. Unfavorable interactions either 
completely prevent binding or require ligands and proteins to adopt suboptimal (high energy) 
configurations. This is observed most obviously if water is considered to be the ultimate high 
concentration fragment, present at 55.5M! Tightly bound water molecules maximize their 
number of interactions (up to four) and water networks are built around these – see for 
example the combined use of theory and experiment to explore such networks in a GPCR.39 
The complexity model separates the probability of a maximally correct binding match of 
possible interacting pharmacophore points from the separate probability of whether the 
number and type of these interactions releases sufficient free energy to be measured in a 
biophysical experiment (Figure 5).  
  
 
 
 
Figure 5. Probabilities of binding and detection as a function of molecular complexity. The 
blue curve represents the probability of a ligand matching the receptor as the complexity of 
the ligand increases. The red curve represents the probability of measuring the binding of a 
ligand to the receptor as the matches increase. The green curve represents the probability of a 
“useful event” which is defined as the product of the red and blue curves. 
 
Hann et al. pointed out that there is a higher probability of a match if there are fewer 
interactions to get right, and that this is most easily achieved when fragments can make only a 
small number of interactions. Several groups have observed this relationship in their 
programs. The Astex group2 showed that the modal value of the Heavy Atom Count (HAC) 
of hits detected from many different fragment campaigns is 12 whereas the modal HAC value 
of the fragment library actually screened is 14.  The Novartis group27 observed HTS hit rates 
of 0.001% - 0.151% in the identification of ligands with an IC50 threshold in the micromolar 
range and fragment hit rates of 3% or more in NMR screening of fragments with an affinity 
  
threshold in the millimolar range. Consequently, the complexity model has been widely 
adopted as a central mantra of the fragment approach and a number of publications have 
looked at both its extension40 and further validation.41,42  
 
One common question is how to relate the complexity model – with its abstract representation 
of molecular interaction points – to the reality of protein-ligand interactions. Because of the 
subtlety and actual complexity of real situations, it is best to use Molecular Complexity as a 
model and not to try to relate the matches to any specific type or strength of molecular 
interactions. However, what is apparent is that molecular interactions that have higher 
information content as represented by, for example, greater directionality or charge gradient, 
are intrinsically harder to position correctly. This is why it is so important to get these 
interactions right during the fragment screening stage (or during initial fragment optimization) 
while the molecule is still unencumbered with substituents.  
 
Ultimately this approach should facilitate the identification of the most efficient optimized 
ligand by prioritizing where and how researchers should focus their efforts as they optimize 
interactions between ligand and target. Molecular interactions with little information content 
(e.g. lipophilic moieties which have minimal directional requirements) can more easily “slide” 
into matching low information regions in the binding site. Aromatic groups can also adapt to 
different environments because of the intrinsic polarizability of such moieties which may help 
to explain their prevalence in fragment hits. A further benefit of getting the maximum reward 
from initial polar interactions in a fragment is that this is generally equated with an enthalpic 
signature to the overall binding free energy. Some evidence suggests that starting with such 
optimized interactions can help minimize the entropic contributions to the free energy (often 
equated with an unwelcome increase in lipophilicity) to build the desired level of potency.4,43 
  
  
Ligand efficiency metrics have been widely adopted in medicinal chemistry to ensure a focus 
on an appropriate balance of physicochemical properties and potency.7 This focus is 
particularly important while developing fragments into quality leads for final optimization. 
Two metrics that are particularly useful in this context are the heavy atom adjusted Lipophilic 
Ligand Efficiency (LLEAT)
44 and Group Efficiency (GE).45 The metric LLEAT (= 0.111 + 
1.37(LLE/HAC)) (where LLE is the Lipophilic Ligand Efficiency (= pKi – cLogP), sometimes 
referred to as LipE) links potency with both lipophilicity and size and is scaled so as to be 
comparable to Ligand Efficiency (LE), whereby an acceptable lower limit for good binding 
sites is considered to be 0.3. The importance of using size-adjusted lipophilic ligand 
efficiency is that the advantages gained by initially using a fragment approach can be easily 
squandered without continued focus on size.6 However, as with all such “rules”, the metrics 
are guides rather than absolutes and due care should be taken when used in a filtering context. 
GE (equal to the free energy gain for the atoms added) helps focus on the contribution of 
different parts of a lead molecule to the overall binding affinity. It is similar to Ligand 
Efficiency but focuses only on the group of atoms that have been added to an initial molecule. 
A recent example of the use of GE is provided by the Abell group during the fragment based 
discovery of leads for Pts, a potential target for tuberculosis.46 Each of these metrics focuses 
on affinity optimization rather than in vivo properties, but they do help control the 
physicochemical properties which are known to be key contributors to success in vivo.47  
 
 
Size and shape considerations 
 
  
The small size of fragments typically yields hits with low affinity and low specificity. These 
features can be correlated with the intrinsically low number of interactions fragments are able 
to form with proteins. Low specificity has two consequences: first, a fragment may be able to 
bind to various proteins, and second, a fragment may be able to bind to a single protein in 
several ways. In the first sense low specificity relates to the high hit rate of fragment screens 
and this is advantageous since specificity can be introduced later in fragment optimization. 
The ability of a fragment to bind to a protein in several ways can frustrate optimization 
schemes, which assume a consistent binding pose to establish structure-activity relationships. 
However, a fragment with multiple binding modes can still be useful in druggability studies. 
They can be incorporated into a well-established procedure to probe proteins with very small 
compounds, such as water and organic solvents both with experimental48 and computational 
methods.49 These compounds with few non-hydrogen atoms bind to proteins and form clusters 
whose positions coincide with those of known inhibitors. Moreover, the extension and relative 
position of these clusters carries significant information on protein druggability.50 
 
A consensus is growing over the ideal size of fragments intended for lead optimization 
projects. Very small compounds are useful in binding site detection and druggablity studies 
but are less suited for fragment screening owing to their versatile binding modes to a single 
protein. According to a Practical Fragments poll, over 85% of responders voted for a 
minimum fragment size between 5 and 10 heavy atoms.51 Clearly, the minimum size is a 
compromise between opposing requirements. One is that a better coverage of chemical space 
is available with smaller ligands as a result of lower molecular complexity; this is a 
fundamental advantage of FBDD. Other requirements are detectable affinity and specificity, 
and these favor larger compounds. As noted above, experiences with crystallographic 
  
fragment screens show that the highest hit rates can be achieved with compounds containing 
10-14 heavy atoms.2  
 
The expansion of a hit to a lead-like compound is facilitated by the existence of a single or at 
least a prevailing binding mode that is preserved during fragment expansion. There have been 
numerous analyses of binding mode conservation of fragments either by cutting larger ligands 
to smaller pieces or the reverse, by analyzing the interactions of larger compounds as they 
were grown from fragments. Several studies obtained direct structural information of binding 
modes. Van Molle et al. investigated the deconstruction of lead-like inhibitors of the 
pVHL:HIF-1α interaction and found that the fragments (including the smallest one with 13 
heavy atoms) maintained the binding pose observed in larger compounds.52 Fry et al. also 
investigated the dissection of inhibitors of a protein-protein interaction and found that the 
smallest fragment with detectable binding contained 20 heavy atoms and exhibited the 
binding mode observed in the full inhibitor.53 Even smaller fragments including 
phenylphosphate with only 11 heavy atoms were found to conserve both the binding site and 
the H-bonding network in the fragments and in the corresponding full length inhibitors in 
complexes with the phospho-tyrosine binding site of the SH2 domain of pp60src.54 Andersen 
et al.55 deconstructed a cyclopentapeptide chitinase inhibitor, argifin, into linear peptides and 
dimethylguanylurea. X-ray crystallographic analysis of the dissected compounds complexed 
with chitinase B1 showed that the conformations of linear peptides were similar to those in 
argifin and that dimethylguanylurea (9 heavy atoms) exhibited all significant interactions 
identified in argifin.  
 
In contrast to these results where fragments obtained by ligand dissection preserved their 
binding mode, Barelier et al. found that fragments derived from Bcl-XL inhibitors do not form 
  
the same interactions as in the full inhibitor; rather they all bind within a single region of the 
protein site.56 Babaoglu and Shoichet deconstructed a -lactamase inhibitor into fragments 
with 8, 11 and 14 heavy atoms and observed that the fragments did not preserve the binding 
mode corresponding to the same moiety in the full inhibitor.57 Satoh et al.58 reported multiple 
binding modes of a ligand to the Nrf2 interaction site of Keap1 and suggested that, based on 
crystallographic and computational studies, the preferred binding mode is different in solution 
and in crystals, and the latter is affected by crystal packing. 
 
In other studies of compound deconstructions, indirect evidence is used to deduce the 
existence of multiple binding modes. Barelier et al. investigated the deconstruction of 
substrates of six enzymes and observed no binding or significant loss in activity even when 
fragments included the key reactive groups.59 Brandt et al. studied the binding of compounds 
obtained by the deconstruction of HIV-1 reverse transcriptase inhibitors bound to an allosteric 
site not present in the apo form of the enzyme.60 Few of the fragment-sized compounds 
showed detectable affinity in surface plasmon resonance experiments and the authors suggest 
the absence of an efficient fragment binding hot spot at the site examined.  
 
Fragments are often optimized by growing them into larger compounds and less frequently by 
linking fragments binding in proximal protein sites. These efforts are often based on the 
assumption of binding mode conservation although this is not always explicitly verified. 
Sometimes, fragment modifications make the question difficult to answer, as the original 
fragment hit within the new compound cannot be definitely identified. Edink et al. were able 
to optimize a fragment hit (17 heavy atoms) bound to an inducible subpocket of 
acetylcholine-binding protein into a larger inhibitor. Binding mode conservation was 
demonstrated by the X-ray structure of complexes formed by the fragment and by the 
  
optimized compound.61 Bauman et al. optimized a fragment (9 heavy atoms) bound in three 
different ways to influenza polymerase acidic protein N-terminal endonuclease domain. A 
fragment chelated to two metal ions was selected and optimized to a larger inhibitor in which 
the binding mode of the starting fragment was preserved.62 Chen and Shoichet identified an 
unselective -lactamase inhibitor (13 heavy atoms) that was optimized into a selective CTX-
M inhibitor. Binding pose conservation was demonstrated by X-ray crystallographic analysis 
of the complexes formed by the fragment and the optimized compound.63 Orita et al. analyzed 
25 fragment optimizations where the complexes of the fragment and the optimized compound 
are both available. They showed that the average root mean square deviation of a core 
structure between fragment hit and lead is well below 1 Å and the hydrogen bonding pattern 
of the fragments is preserved in the optimized compounds.64 
 
The cited examples clearly show that fragments typically having 10 to 20 heavy atoms are 
able to bind specifically to a variety of protein binding sites including polar pockets and 
protein-protein interfaces. The specific binding is proven by the conservation of the binding 
mode as the fragments are grown to larger inhibitors. However, there are many cases where 
the binding mode of a fragment does not agree with that of the corresponding moiety in a 
larger compound. An explanation of these differences was proposed by Kozakov et al.65 based 
on the varying overlap of the bound fragments with the primary hot spot. They also propose a 
simple method based on their computational solvent mapping protocol49 to identify primary 
hot spots as sites where the highest number of clusters of various probe compounds bind. A 
possible interpretation of this finding is that a site that binds various small probes contains a 
diverse set of proximal binding functions that interact collectively with fragments having 
appropriate pharmacophore features. This explains what was convincingly shown in several 
examples that fragments bound with appropriate overlap with the hot spot of consensus 
  
clusters preserve their binding mode,65 while those bound at the site of other clusters may 
change their binding mode upon structure expansion. It is also consistent with the fact that 
although fragments are versatile binders with the ability to bind to various protein targets, 
they can also be evolved to higher specificity for the more druggable targets. For these latter 
proteins a primary hot spot is available that is able to bind certain fragments specifically with 
an affinity not available for the same ligands at other protein sites. 
 
Kozakov et al. argue that the intrinsic binding potential of the protein site has a decisive role 
in the conservation of the binding mode.65 They suggest that secondary binding sites tend to 
have less potential to conserve binding modes for fragments and their larger derivatives. 
Whether this is indeed the case is an important question since targeting secondary binding 
sites by fragments both in enzymes66 and in GPCRs67,68 has been gaining increased attention. 
In addition to the binding potential of the protein site, structural features of the fragments are 
also critical for both binding and specificity. An analysis of experimental fragment-protein 
complexes in the Protein Data Bank69 revealed that fragments form on average two optimal 
geometry hydrogen bonds with the protein hot spot.43 Some typical examples are shown in 
Figure 6. Binding pharmacophores that have been identified from the analysis of molecular 
interactions can be useful in the design of fragment libraries. Ideally a variety of fragments 
that contain each of the binding pharmacophores should be included in the library.70  
 
 
 
  
Figure 6. Crystal structures of fragments exhibiting key binding pharamcophores. Chemical 
structures are also given with the binding pharamcophore marked in blue. (a) amidine-like 
pharmacophore in beta secretase (PDB Code: 2OHK). (b) A donor acceptor pharmacophore in 
protein kinase A (PDB Code: 2UW3). 
 
The presence of a few directional polar interactions in a predominantly apolar environment 
contributes to the strength and specificity of the binding and is in line with the properties of 
hot spots.71,72,73,74 It was also found that less polar fragments tend to bind with lower affinity 
and more promiscuously.29,56,75 
 
It seems that the presence of a strong hydrogen bond in the initial fragment indicates that a 
strong anchor point is likely to be maintained.64 If the fragment does shift, it likely had 
multiple orientations in the first place, possibly disguised in poorly defined electron density. 
Alternatively, a stronger set of interactions may have been made in the optimization processes 
which overcame initial weak binding; this possibility can be particularly pertinent where 
synergy between interactions takes place, which is not possible in the smaller molecules. It is 
therefore important to continue to check ligand position and orientation throughout the 
fragment evolution process, particularly when unexpected SAR is encountered.  
 
By contrast, potency driven by lipophilicity has been well documented to be a source of non-
specific promiscuity and a good fragment hit can easily be squandered by inappropriate use of 
lipophilicity.6,41,76,77 This promiscuous binding seems intrinsic to lipophilic interactions and 
has been interpreted in the molecular complexity model as resulting from the low information 
content of such interactions.42 
 
  
A further topic relevant to binding specificity is the competitive or simultaneous binding of 
two or more fragments. This can happen when fragments are pooled together to improve the 
throughput of a screening technique. In ligand-observed NMR screening it is usually possible 
to identify multiple hits from a pool of fragments provided that the NMR spectra of the 
fragments do not overlap. In X-ray screening, it is important that fragments within a pool have 
shape diversity so that hits can be identified more easily. However, even a clear X-ray hit 
does not preclude the possibility that another fragment from the pool can bind at the same site. 
Further deconvolution experiments may therefore be required, and if the hit rate is high, it 
may be more efficient to screen compounds individually. The synergistic binding of two or 
more fragments may also interfere with the deconvolution of hits in X-ray screening of 
fragment cocktails. If the individual fragments do not bind strongly enough for detection they 
would be considered as false positives and yet the cooperative binding of the two fragments 
would provide valuable information to identify chemical starting points for developing potent 
inhibitors.78 One benefit of having two fragments bound to proximal sites is the possibility of 
using fragment linking, 79 a theoretically attractive concept which unfortunately is not often 
successfully achieved. The challenge of fragment linking may be that at least one fragment 
will likely bind outside the principal hot spot, making the initial pose hard to maintain when 
this fragment is expanded.65 Nevertheless, there are successful applications of fragment 
linking with significant affinity increases.80,81 In these cited examples the significant affinity 
gain is achieved by linking fragments having not more than 15 heavy atoms. Moreover, the 
linking coefficient, defined as the difference between the affinity of the final ligand and the 
sum of fragment affinities is near to the estimated rigid body entropy loss of binding82 
suggesting that fragments can sometimes be linked without introducing strain or altering 
poses. 
 
  
The appropriate shape of fragments garners much debate. Fragment libraries have 
traditionally been dominated by compounds with somewhat planar rings (such as 
pyrimidines), although some evidence suggests that non-aromatic compounds lead to 
improved quality of final clinical candidates.83,84 However, this evidence has been 
challenged,85 and it is fair to say that calculating physicochemical properties is no substitution 
for experimental measurements. 
 
Nonetheless, the strategy of boosting “three dimensionality” of ligands is much discussed as a 
way to reduce promiscuity and improve solubility and thus ultimately improve the 
developability of ligands. This in turn has resulted in moves to measure and increase the 3D 
character of fragments.86,87  However, this increased 3D character could result in an increase 
in the complexity of the fragments and thus lead to a reduction in the probability of any one of 
them matching the receptor. This can be partially abrogated by increasing the number of 
fragments screened, but this brings other problems in terms of the capacity of biophysical 
screening methods. Additional impetus to increase the presence of 3D fragments in libraries is 
the proposal that this leads to a broader coverage of biologically relevant chemical space and 
may be especially beneficial for challenging targets.86  Nevertheless, initial studies suggest 
that hit rates for 3D fragments are lower than those for flatter compounds and this is 
consistent with the higher complexity of 3D fragments.2 These considerations suggest that 
taking maximum advantage of FBDD hinges on a sensitive balance between complexity, size 
and diversity of fragments. 
 
 
Target related aspects 
 
  
It is a truth universally acknowledged that not all proteins can be targeted with small 
molecules. Those that can are referred to as “ligandable.”8 This term is preferable to the term 
“druggable,” since a target may be ligandable even though it ultimately has no role in a 
disease. Indeed, since validating a therapeutic target often first requires identifying a small 
molecule modulator, researchers usually need to establish whether a target is ligandable 
before establishing whether it is ultimately druggable. Even within target classes that have 
been shown to be ligandable there is considerable variability in the molecular weight, polarity 
and lipophilcity of typical ligands with drug-like potencies.88 Many attempts have been made 
to use computational methods to assess ligandability89,90 but fragment screening has also 
proven to be an effective experimental means to assess ligandability. Multiple studies have 
shown that the hit rate from a fragment screen correlates well with the hit rate from high-
throughput screening (HTS) and the ultimate success of lead optimization.75,89,91  
 
Some targets, such as many enzymes, have a well-defined pocket that has evolved to bind 
small molecules, so it is not surprising that many fragments bind in these substrate binding 
sites, often making some of the same interactions as the natural substrates. For example, 
screens against kinases often yield fragments that bind in the adenosine binding site, and these 
often have high ligand efficiency values. On the other hand, protein-protein interfaces often 
consist of large, flat surfaces with few or no pockets, and fragment screens against such 
targets are usually less successful. Consequently, ligand efficiency values of ligands that 
disrupt protein-protein ligands tend to be lower (see below).92 
 
Historically most FBDD programs have targeted enzymes or other soluble proteins, and 
fragment screening is much more challenging on, for example, membrane proteins. However, 
significant progress has been made in this latter area through the use of thermally stabilized 
  
membrane proteins which are selected by effective use of mutagenesis studies.93 After 
stabilization the protein is more amenable to standard assay techniques such as SPR, Thermal 
Shift and X-ray based FBDD experiments. 
 
One point of debate in fragment library design is whether fragment libraries should be target-
directed or general. For example, since kinases have evolved to bind ATP, it might make 
sense to design a kinase-directed library consisting of moieties that bind to the region 
responsible for binding the adenine part of ATP.94 This approach has indeed been quite 
successful, as noted in Table 2, and many companies and commercial vendors have built 
custom libraries for specific target classes. A potential drawback is that the resulting 
fragments are less likely to be novel. However, this should not necessarily be a major 
consideration as much of the intellectual property is created during fragment to lead 
optimization and beyond. For example, both vemurafenib95 and the clinical candidate 4-
amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-
yl)piperidine-4-carboxamide (AZD5363) 96 had their origins in a common 7-azaindole 
fragment, yet ultimately their structures and properties dramatically diverged. Indeed, the 
azaindole scaffold is such a fruitful source of fragments that an entire review was devoted to 
it.97 A more serious objection to target-based libraries is that sometimes the most interesting 
hits are the least expected; it is hard to design for serendipity. For example, a screen against 
PAK1 identified a fragment with scant resemblance to adenine. This binds outside the ATP-
binding site and led to allosteric molecules that are remarkably selective for the kinase.98  
 
A related issue is selectivity: how selective should a fragment hit be? Researchers accustomed 
to working with HTS hits may instinctively prefer more specific fragment hits, but as the 
azaindole discussion above demonstrates this is not necessarily justified. Indeed, on the basis 
  
of the molecular complexity argument, fragments should theoretically not be very selective or 
it would be impossible to get hits from a small library. That said, it is not uncommon to find 
fragments that show specificity. Bamborough and colleagues at GlaxoSmithKline 
demonstrated this experimentally by screening nearly 1000 fragments against 30 kinases.26  
These fragments were chosen to be likely to bind to the ATP hinge region of kinases, yet 
many of them proved to be quite selective. Even adenine, which should after all bind to all 
kinases, strongly inhibited less than half of them. However, when the researchers looked at 
larger molecules that contained these fragments, there was no correlation between the 
selectivity of the fragments and that of the more potent, elaborated molecules. Recent work 
from the Collins group showed similar results from fragment-to-lead programs, and also 
demonstrated that very small changes to a molecule could have drastic effects on selectivity.99 
In other words, it is possible to start with a non-selective fragment (such as 7-azaindole) and 
develop a selective inhibitor (such as vemurafenib). On the other hand, it is also all-too-
possible to start with a selective fragment and end up with a non-selective inhibitor, especially 
by adding inappropriate levels of lipophilicity. 
 
As hinted at above, one effective way to address selectivity among related targets is to 
sidestep the common active site entirely and focus on allosteric sites. Due to their ability to 
bind to small, sometimes cryptic binding sites, fragments are ideally suited for identifying 
allosteric sites. In fact, a crystallographic fragment screen from the Arnold group at Rutgers 
University revealed 16 different binding sites on HIV Reverse Transcriptase, though the 
function of many of these is uncertain.100 Allosteric kinase inhibitors are well-precedented and 
often quite selective;101 as noted above an allosteric PAK1 inhibitor derived from a fragment 
screen at Novartis appears to be >50-fold selective for the enzyme compared to 441 other 
kinases.98 Novartis has also started clinical development on an allosteric ABL inhibitor.102 
  
 
Allosteric modulators can also be effective against difficult targets. For example, caspases are 
a family of cysteine proteases with charged, extended binding sites, making it difficult to 
discover specific drug-like leads. A collaboration between Genentech and UCSF revealed 
fragments that bind to an allosteric site on procaspase-6 and stabilize this inactive zymogen 
form.103 Another example of using allosteric modulators to prevent enzyme activation was 
published by researchers from Astex, who performed a fragment screen against the hepatitis C 
protein HCV NS3 and found fragments that bind between the protease and helicase domains. 
These were ultimately optimized to low nanomolar potency with cell-based activity.104 
 
As mentioned above, protein-protein interactions (PPIs) tend to be more difficult than 
conventional targets, as reflected in lower hit rates from both high-throughput and fragment 
screens. Nonetheless, fragment screens have been successful in multiple cases.105 One of the 
most prominent examples is work done by researchers at AbbVie in which they used SAR by 
NMR to identify fragment hits against the anti-cancer target BCL-xL. After extensive 
medicinal chemistry, these were ultimately optimized to navitoclax.106 Further modification of 
this scaffold led to venetoclax, 107 which is selective for the related protein BCL-2 and is 
reportedly on track for FDA approval in 2016. Fragment screening has also been successfully 
applied to discover inhibitors against another member of this protein family, MCL-1108,109 as 
well as against RAD51.110 
 
Due to the difficult nature of PPIs, higher concentrations of fragments are often necessary to 
find hits with even low ligand efficiency. Carefully done, however, this can be highly 
effective, as demonstrated by a recent study from researchers at Astex. An NMR screen of 
fragments at 10 mM revealed a very weak hit against the anti-apoptotic proteins cIAP1 and 
  
XIAP. Unlike most previously reported molecules, this had comparable activity against both 
proteins, and structure-guided medicinal chemistry was successful at generating nanomolar 
inhibitors with cell-based activity.38 
 
Another difficult target that has recently succumbed to fragments is Ras. Researchers at 
Genentech and Vanderbilt University independently used NMR screening to identify 
fragments that bind to a small surface-exposed pocket and block interactions with the 
exchange factor SOS.111,112 
 
For particularly difficult targets, covalent bond formation can be effective at identifying low-
affinity fragments; the bond can stabilize interactions that may be too weak to detect using 
other approaches. This was the idea behind Tethering, which relies on thermodynamically-
driven disulfide exchange between a cysteine residue in the protein and libraries of disulfide-
containing fragments.113,114 The challenge with disulfide bonds is that they need to be 
replaced to be effective in cells, let alone animals. However, researchers at UCSF 
demonstrated that this replacement could be accomplished against a mutant form of K-Ras 
containing an activating cysteine residue.115 
 
Covalent drugs have undergone a renaissance of sorts, and this has propagated through to 
libraries of designed covalent fragments. The Statsyuk group at Northwestern University has 
designed libraries of acrylate-containing fragments and shown that selective inhibitors can be 
found against different proteins.116 Unlike in the case of Tethering, these fragments form 
irreversible bonds to the protein, so it is important that the intrinsic reactivities of the 
fragments do not vary too much. Somewhat sidestepping this issue, the Taunton group at 
UCSF has generated cyanoacrylamide-containing fragments, which can form reversible 
  
covalent bonds with cysteine residues. These were used to develop potent, selective kinase 
inhibitors.117 Computational methods can be successfully applied to identify covalent 
inhibitors, and a program developed by Shoichet and colleagues at UCSF is freely 
available.118 
 
 
Synthesis related aspects  
 
When a fragment screening library is used to provide hits to start a drug discovery program it 
is important that the hits obtained are “optimizable”. That is, there is a high likelihood that 
when a fragment binds to the target protein there will be accessible positions available to 
further exploit the hit chemically. This concept of optimizability has been built into fragment 
screening sets in a number of different ways. One approach is to ensure that a fragment has a 
defined synthetic handle.16 One challenge here is that polar moieties such as acids or amines 
can often provide the key interaction in a lower molecular weight fragment and any synthetic 
modification could change the nature of the group (e.g. by amide formation).119 
Schuffenhauer et al.27 overcame this problem by developing a reaction dictionary that allowed 
the searching of fragments that mask the reactive functionality. Lau et. al.28 used experienced 
medicinal chemists to judge the chemical expandability of fragments in the development of a 
fragment screening library at Pfizer. It is also possible to provide an in silico assessment of 
“optimizability”37 to guide in the triaging of thousands of potential fragments. A RECAP 
like120 approach was used to identify the “core” for each fragment by trimming back to 
potential reactive groups and a substructure search in internal and external data sources was 
able to identify the number of substitution positions on the fragment, allowing ranking of 
fragments. Cox et al. have described the design of a poised fragment library where fragments 
  
derived from simple synthetic reactions are included in the library so as to facilitate the rapid 
synthesis of analogs of fragment hits.121   
 
Historically, fragment libraries have used substructures derived from drugs as one of the 
sources of ideas.122 Pihan et al.123 have provided a set of commercially available fragments 
based on substructures of drugs. However, Morley et al.86 have analyzed a number of 
fragment libraries using principal moments of inertia (PMI) plots and suggest that they have 
limited shape diversity when compared to fragments derived from compounds tested in 
humans. They describe the 3D Fragment Consortium which has a goal to provide additional 
compounds with greater three dimensionality. Hung et al. have exploited diversity-orientated 
synthesis as a method for generating 3D fragments.124 Natural products have been a rich 
source of drugs and tend to have a much higher sp3 content than synthetic compounds.125,126 
Over et al.127 describe an analysis of natural products to determine a set of natural product-
derived fragments rich in sp3 carbon atoms. The library was validated by screening against 
p38 kinase and identifying an atypical non-aromatic kinase fragment binding in an allosteric 
site. Vu et al.128 describe the creation of a natural product library of fragment sized 
compounds, identifying compounds binding to Plasmodium falciparum 2’-deoxyuridine 5’-
triphosphate nucleotidohydrolase (PfdUTPase). However, care must also be taken when 
designing natural product fragment libraries, and many of the other principles described in 
this Perspective should still be applied, of particular concern being the increase in molecular 
complexity and synthetic tractability associated with increasing the sp3 content. Furthermore, 
some natural products contain many groups that are considered PAINS21 and in isolation 
would be very problematic in terms of selectivity and mode of action, for example quinones 
and catechols.  
  
Many commercial vendors offer fragment libraries derived from their own synthetic 
compounds, marketed drugs and/or natural products129 and a number of CROs also claim 
unique fragment libraries as part of their offering, some of which are highlighted in Table 5. 
A brief summary of the design principles behind each set is also given where available. 
Greater detail can be found in the references and links in the table. Most of these libraries are 
designed within the bounds of the Rule-of-Three9 and many vendors now have tens of 
thousands of fragment like compounds available. Fluorine-containing libraries are available 
for 19F NMR and bromine-containing libraries for exploring halogen bonding effects130 and 
facilitating crystallographic screening. There are also a number of specialized libraries for 
specific target classes and covalent binding. A full assessment of these offerings is beyond the 
scope of this review, and indeed comparison is difficult without knowing the purpose or target 
of the campaign. However, the guidelines given throughout this review should prove useful in 
guiding the reader to select fragments from commercial sources. These include querying the 
available measured solubility and purity, applying substructure filters and selection algorithms 
appropriate to the target(s), and assessing the compounds for undesirable features and 
“optimizability” either by visual inspection or algorithmically. Chris Swain has analyzed the 
physicochemical properties of some of these libraries,131 though it is important to note that 
vendors do periodically change the compositions of their libraries. 
 
Despite the availability of fragment sets from commercial sources, there is a need for 
continuing development of novel fragments to tackle new targets. The impact of synthetic 
methodology on the properties of the resulting molecules has been recognized in the context 
of lead discovery,132 emphasising the role of the synthetic chemist in addressing these issues.  
In a recent essay,70 Murray and Rees have called on the chemistry community to increase 
research in the development of novel synthetic chemistry methodology, particularly with 
  
regard to fragment-sized compounds . In particular they highlight the need to more thoroughly 
explore and describe the synthetic routes to all potential growth vectors prior to screening 
because much time can be spent in the initial phases of optimization developing appropriate 
chemistry. The further development of approaches to C-H functionalization133 and use of 
high-pressure continuous flow methods to give novel heterocycles134 are some examples of 
recent chemistry developments that can be exploited in the synthesis of novel fragments.  
 
Vendor Website Library # cmpds Commercially 
available 
3D Fragment 
Library 
Consortium 
Ref. 86 Increased shape 
diversity 
through greater 
three 
dimensionality 
>500135 N 
ACB Blocks www.acbblocks.com 19F NMR-
oriented, RO3 
compliant, 
predicted to be 
soluble. Purity 
> 96% 
1280 Y 
Analyticon www.ac-discovery.com FRGx: 
Fragments from 
Nature. RO3 
compliant, high 
solubility, 
purity > 95%. 
213 Y 
  
AnCoreX www.ancorex.com MetaKel™ 
(metal 
chelating. MW 
< 300) 
TCI-Frag™ 
(Targeted 
covalent 
inhibitor 
fragment 
screening. 
Mildly reactive 
functionalities, 
RO3 compliant) 
>500 
 
 
 
>100 
N 
Asinex www.asinex.com  Fragment 
library 
22,524 Y 
Beactica www.beactica.com SPRINT. 
Validated for 
SPR. 2000 
purchased 
fragments. 
1946 N 
Beryllium www.be4.com Fragments of 
Life™.138 
1,500 N 
BioBlocks www.bioblocks.com Proprietary 
fragment 
library based on 
exploration of 
3D shapes. 
~1000 N 
  
Charles River www.criver.com Core fragment 
library, 500 
member kinase 
focussed set 
and 500 
member 19F 
labelled. 
1,500  
 
N 
ChemBridge www.chembridge.com ChemBridge 
Fragment 
Library, RO3 
compliant with 
predicted 
solubility. 
Minimum 
purity 90% by 
1H NMR. 
>7,000 Y 
ChemDiv www.chemdiv.com 3D designed 
fragment 
library 
4,283 Y 
Enamine www.enamine.com RO3 compliant 
Golden 
Fragment 
Library (diverse 
subset of full 
library), 
“simple” 
fragment 
18,108 
1,794 
 
 
 
 
126,597 
 
Y 
 
  
library: RO3 
compliant <=20 
heavy atoms 
from screening 
collection. 
Other smaller 
sets of 
fluorinated, 
brominated (for 
X-ray), 
covalent sp3 
rich and PPI 
fragments. 
 
 
 
 
 
 
InFarmatik www.infarmatik.com Consolidated 
library from 
different 
concepts, 
In3D,GPCR, 
Kinase 
1700 Y 
 
IOTA www.iotapharma.com Diverse, mainly 
RO3 compliant. 
1,500 Y 
Integrex www.integrexresearch.com Diversity in 
shape and 
chemical 
structure, RO3 
allowing one 
violation. 
1,500 Y 
  
Key Organics www.keyorganics.net Fragment 
library 
2nd Generation 
with assured 
aqueous 
solubility, RO3 
compliant. 
Fragments from 
Nature, RO3 
compliant, 
assured 
solubility and 
high Fsp3 
content. 
CNS fragment 
library. More 
stringent filters 
(e.g. mw<240) 
Fluorine 
Bromine 
26,000 
 
1166 
 
 
 
 
183 
 
 
 
 
 
 
700 
 
 
 
1,950 
1,656 
Y 
 
Life Chemicals www.lifechemicals.com General 
RO3 
compliant(and 
subsets of 
predicted 
soluble, 
Fluorinated, 
31,000 
14,000 
 
 
 
 
 
Y 
 
  
Brominated and 
Fsp3 enriched, 
Covalent and 
PPI focused) 
Maybridge www.maybridge.com RO3 compliant 
Diversity 
Fragment 
library with 
assured 
solubility in 
DMSO and 
PBS buffer. 
1,000 fragment 
subset 
available. 
 
Fragment 
collection, 
filtered by 
purity, mw<350 
and 
substructures. 
2,500 
 
 
 
 
 
 
 
 
 
 
 
>30,000 
Y 
Otava www.otavachemicals.com General RO3 
compliant, 
predicted to be 
soluble. 
Assured 
12,486 
 
 
 
1,000 
Y 
  
solubility in 
DMSO and 
PBS 
Fluorine 
Metal chelator 
Halogen-
enriched with 
Bromine for X-
ray studies. 
 
 
 
1,217 
1,023 
618 
Prestwick 
Chemical 
www.prestwickchemical.com  Prestwick 
Fragment 
Library mainly 
derived from 
drug fragments, 
Ro3 compliant. 
910 Y 
Selcia www.selcia.com Selcia 
Fragment 
Library, RO3 
compliant, 
predicted and 
measured 
solubility with 
purity > 95%. 
1,400 Y 
TimTec www.timtec.net Fragment-based 
library 
structurally 
diverse with 
3,200 Y 
  
predicted high 
solubility. 
Vitas-M www.vitasmlab.com RO3 compliant. 18,932 Y 
Zenobia www.zenobiafragments.com Fragment 
library from 
different design 
paradigms, 
cores from 
drugs, higher 
Fsp3 flexible 
cores etc. 
968 Y 
ZoBio http://www.zobio.com/ RO3 compliant 
diverse 
commercially 
available and a 
smaller 
proprietary 
library. 
2,300 N 
 
Table 5. Selected list of vendors and CRO fragment libraries, highlighting the range of 
libraries on offer in terms of design principles and numbers. 
 
Management of fragment libraries 
 
Management of fragment libraries is prosaic yet critical. The first step is to make sure that 
every fragment that enters the library passes acceptable purity criteria, typically 90-95%. At a 
minimum this should be established by HPLC-MS, but preferably this will be confirmed by 
  
NMR. If NMR will be used as part of the screening process, it will be important to obtain 
spectra of the compounds anyway, so purity can be established with minimal extra effort. 
Recognizing the importance of this, some commercial vendors have started including NMR 
spectra for their fragment libraries. However, this should not substitute for in-house 
confirmation: an analysis by Darren Begley, then at Emerald Biosciences, found that 16% of 
samples across a set of >10 vendors failed QC, with failure rates as high as 33% in some 
cases.136  
 
In addition to the working library, it is essential to have access to dry stocks of fragments for 
confirmation experiments. When Pfizer built its fragment library, the requirement was that at 
least 200 mg of material was available for in-house compounds.28 When purchasing 
compounds from a commercial vendor, it is prudent to check availability. It is all too common 
(and frustrating) to find that a fragment is no longer available months or years later when it 
shows up as a screening hit.  
 
DMSO is almost always the solvent of choice for fragment screening libraries. If NMR will 
be used at some point, it makes sense to dissolve the fragments in deuterated DMSO, 
particularly since the added cost is minimal. Compounds are typically dissolved at a 
concentration of at least 50 mM to minimize the amount of solvent introduced into the assay: 
a final concentration of 1 mM fragment would give 2% DMSO. Even higher concentration 
stocks are advantageous in reducing the amount of organic solvent in the final assay. For 
example, researchers at Monash University prepared their fragment libraries at 200 mM.137 
However, this comes with the risk that fewer fragments will be soluble.  
 
  
Besides DMSO, the only other solvent that has been used to any extent is methanol; due to its 
volatility it can be used to add larger amounts of fragments to a crystallization plate without 
changing the final buffer composition.138 However, this approach does not appear to have 
been used widely. The low surface tension of methanol makes it harder to precisely aliquot, 
and fragments may not easily redissolve in buffer once they have dried onto a plate. 
 
Compound stability is also not to be taken for granted. Most fragment libraries are prepared in 
DMSO, which is slightly oxidizing, and some compounds can rapidly degrade in it.139 Even 
water is not necessarily benign: seemingly stable moieties such as benzoxazoles can 
hydrolyze, even when stored as solids.140 In another case a library compound cyclized in 
DMSO to form an active species, but this in turn proved to be unstable in water, complicating 
assay interpretation.13 Thus, best practice is to periodically (often annually) reevaluate 
fragment libraries to ensure their integrity.141  
 
There is some debate as to how best to store fragment stock solutions. A study of 7200 
compounds stored in DMSO at room temperature at Procter and Gamble found that while 
only 8% had degraded after 3 months, this had increased to 17% after 6 months and a 
whopping 48% after 1 year.142 Storing DMSO solutions frozen would seem to be a solution, 
but the resulting freeze-thaw cycles are themselves problematic, particularly as they increase 
the likelihood of introducing atmospheric water into the DMSO, which is highly hygroscopic. 
Compound solubility in DMSO has been reported to decrease dramatically in the presence of 
even small amounts of water.143 Consistent with this, a study of 232 compounds subjected to 
repeated freeze-thaw cycles showed precipitation and decreased concentrations compared to 
compounds that had been stored frozen or even at room temperature.142 It is important to note 
  
that the molecules used in these studies were not fragments, and it is possible that larger 
molecules have higher odds of instability and precipitation. 
 
Although pure DMSO freezes at around +19 ˚C, compound stocks at 100 mM or more often 
remain liquid even at low temperatures. Thus, a common strategy is to store fragment stocks 
at low temperatures to slow decomposition but minimize freeze-thaw cycles. In a poll taken at 
Practical Fragments in early 2014, more than half of respondents reported storing fragment 
libraries at +4 ˚C or – 20 ˚C, while nearly a third kept their libraries at room temperature 
(Figure 7).144 Keeping libraries under inert gas in low humidity is also good practice. 
 
Figure 7. Results of a poll taken on Practical Fragments in January and February 2014 asking 
how fragment libraries are stored; there were 79 responses.144  
 
 
 
Perspectives, conclusion  
 
Fragment-based drug discovery is well-established in industry and has resulted in more than 
30 drugs entering clinical trials,145 with one – vemurafenib – already approved. FBDD also 
  
has key attractions for academia. Notably, it is able to tackle difficult or novel targets for 
which no chemical matter may be found in existing HTS collections. Moreover, establishing 
and screening a fragment library, which can be as small as a few hundred compounds, is far 
less expensive and challenging than working with a standard HTS collection of 500,000+ 
compounds. 
 
However, precisely because fragment libraries are small, the outcome of FBDD programs is 
very much dependent on the initial fragment hits, so it is essential that these are carefully 
selected. Design of fragment libraries requires the consideration of multiple factors that often 
contradict each other, complicating the process. 
 
At a minimum, fragment libraries should be purged of compounds known to be generically 
reactive or that interfere with common assays, including PAINS such as quinones and redox 
cyclers such as toxoflavin. Certain types of compounds that repeatedly show up as screening 
hits but rarely yield structural information, such as PrATs, should probably also be avoided. 
On the other hand, “non-selectively specific fragments” that bind to multiple proteins through 
well-characterized interactions, such as 7-azaindole and 4-bromopyrazole, may be useful 
additions to a fragment library. 
 
Simple filters based exclusively on physicochemical properties have a role – there is no place 
for a massively lipophilic 500 Da molecule in a fragment library – but as with all of drug 
discovery these should be seen as guidelines rather than hard and fast rules. On the other 
hand, high solubility is critical, and this should be measured experimentally. 
 
  
Other factors are harder to prescribe. Molecular complexity impacts the affinity and 
specificity against targets, but is more difficult to measure. In general smaller, simpler 
fragments are likely to be more useful, while fragments with multiple stereocenters or more 
three-dimensional shapes may provide lower hit rates.37 
 
Synthetic considerations are important too: it can be frustrating to discover a fragment binding 
perfectly in a target only to find that growing in the desired direction requires developing 
unprecedented chemistry. A good practice is to ensure that multiple analogs of any fragment 
included in the library are available, either commercially or in-house. Given the limited 
diversity of available protein binding sites, together with the small relative size of fragments, 
the size and diversity of the library – assuming a reasonable minimum – are probably less 
important. 
 
The overall quality of the fragment library depends on physical factors too, of which purity, 
stability and storage conditions are clearly the most important. Periodic assessment of the 
fragment library for degradation, and confirmation of any hits with fresh sample, are essential 
practices. 
 
The success or failure of discovery programs is very much influenced by the screening hits. 
Since the quality of hits is determined by the screening technology and the library screened, 
updated design principles of fragment libraries will hopefully contribute to the increased 
success rate of FBDD programs. Table 6 contains guidelines we would recommend when 
constructing a fragment library or when considering the addition of new fragments to an 
existing library. As discussed throughout, these guidelines should be considered in the context 
of both the biological target and the fragment screening technique.  
  
Building on more than a decade of screening fragment libraries, we hope that this paper will 
promote wider adoption of fragment-based approaches by helping to improve the quality of 
fragment libraries and associated screening technologies. 
 
 
Property Guideline  
Library size 500 – 3000 fragments (smaller libraries are more 
appropriate for lower throughput screening methods 
(e.g., x-ray) and larger libraries are more appropriate 
for higher throughput methods (e.g, SPR)) 
Physico-
chemical 
properties 
 
 
 
                                                                                                  
 
Molecular weight: ~140-230;  
Non-hydrogen atoms: 9-16; 
(Fragments at the lower end of the size range are more 
appropriate for lower throughput, higher sensitivity 
screening methods) 
Lipophilicity (cLogP):  ~0.0 to 2.0;  
Number of freely rotatable bonds: 0-3;
Number of chiral centres: 0-1, sometimes 2. Always 
use racemates. 
Properties commensurate with biophysical screening at 
high concentrations, e.g., aqueous solubility (preferably 
≥5mM in 5% DMSO, or other screening co-solvents); 
stability (>24h in solution); avoid 
compounds/functional groups known to be associated 
  
with high reactivity, aggregation in solution, or false 
positives.  
Molecular 
recognition  
Diverse, usually polar groups for binding to a protein (a 
single pharmacophore). An aspiration is to express any 
given binding pharmacophore in a variety of diverse 
scaffolds (chemotypes). 
Shape Variety of 2- and 3-dimensional shapes for each 
scaffold and pharmacophore; 
Availability of 
analogs 
Fragments should contain multiple synthetically 
accessible vectors for fragment growth in 3 dimensions 
to access new binding interactions. Fragments should 
be synthesizable in <4 steps from commercial available 
starting materials. Under some circumstances it may be 
desirable to choose fragments that are commercially 
available and/or have many commercially available 
analogs 
Diversity Diversity metrics should be used to prevent the 
inclusion of close analogs in the library. Care should be 
taken to ensure the diversity metrics do not favor the 
selection of larger fragments over simpler examples 
and that appropriate descriptors and similarity cutoffs 
are used. 
 
  
 
 
 
 
 
Table 6. Recommended guidelines for construction of a fragment library. 
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